A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer
Raghunadharao Digumarti, Yenyun Wang, Ganapathi S. Raman et al. · Journal of Thoracic Oncology · 2011
Cited by 69 works. doi:10.1097/jto.0b013e3182156250
Authors
- Raghunadharao Digumarti
- Yenyun Wang
- Ganapathi S. Raman
- Dinesh Chandra Doval
- Suresh Hariram Advani
- Pramod Kumar Julka
- Purvish Mahendra Parikh
- Shona Milon Nag
- Jayaprakash Madhavan
- Ajay Bapna
- Arati Ranade
- Atul Varadhachary
- Rajesh K. Malik
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Lactoferrin
- A System for Production of Commercial Quantities of Human Lactoferrin: A Broad Spectrum Natural Antibiotic
- Lactoferrin Acts as an Alarmin to Promote the Recruitment and Activation of APCs and Antigen-Specific Immune Responses
- Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy
- Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells
- Oral Administration of Lactoferrin Inhibits Inflammation and Nociception in Rat Adjuvant-Induced Arthritis
- Phase I trial of oral talactoferrin alfa in refractory solid tumors